|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wink KC, Roelofs E, Solberg T, Lin L,
Simone CB II, Jakobi A, Richter C, Lambin P and Troost EG: Particle
therapy for non-small cell lung tumors: Where do we stand? A
systematic review of the literature. Front Oncol. 4:2922014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bray F, Jemal A, Grey N, Ferlay J and
Forman D: Global cancer transitions according to the Human
Development Index (2008–2030): A population-based study. Lancet
Oncol. 13:790–801. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Grose D, Morrison DS, Devereux G, Jones R,
Sharma D, Selby C, Docherty K, McIntosh D, Nicolson M, McMillan DC,
et al: The impact of comorbidity upon determinants of outcome in
patients with lung cancer. Lung Cancer. 87:186–192. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mehta A, Dobersch S, Romero-Olmedo AJ and
Barreto G: Epigenetics in lung cancer diagnosis and therapy. Cancer
Metastasis Rev. 34:229–241. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vasudevan S, Tong Y and Steitz JA:
Switching from repression to activation: microRNAs can up-regulate
translation. Science. 318:1931–1934. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
van de Vrie M, Heymans S and Schroen B:
MicroRNA involvement in immune activation during heart failure.
Cardiovasc Drugs Ther. 25:161–170. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Garzon R, Marcucci G and Croce CM:
Targeting microRNAs in cancer: Rationale, strategies and
challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Joshi P, Middleton J, Jeon YJ and Garofalo
M: MicroRNAs in lung cancer. World J Methodol. 4:59–72. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li F, Liu J and Li S: MicroRNA 106b ~25
cluster and gastric cancer. Surg Oncol. 22:e7–10. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chaluvally-Raghavan P, Zhang F, Pradeep S,
Hamilton MP, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, et
al: Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of
TP53INP1 and aggressiveness of epithelial cancers. Cancer Cell.
26:863–879. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kawano O, Sasaki H, Okuda K, Yukiue H,
Yokoyama T, Yano M and Fujii Y: PIK3CA gene amplification in
Japanese non-small cell lung cancer. Lung Cancer. 58:159–160. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Go H, Jeon YK, Park HJ, Sung SW, Seo JW
and Chung DH: High MET gene copy number leads to shorter survival
in patients with non-small cell lung cancer. J Thorac Oncol.
5:305–313. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Qian J and Massion PP: Role of Chromosome
3q amplification in lung cancer. J Thorac Oncol. 3:212–215. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Di Cello F, Hillion J, Hristov A, Wood LJ,
Mukherjee M, Schuldenfrei A, Kowalski J, Bhattacharya R, Ashfaq R
and Resar LM: HMGA2 participates in transformation in human lung
cancer. Mol Cancer Res. 6:743–750. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu Y, Song Y and Liu H: Expression and its
clinical significance of HMGA2 in the patients with non-small cell
lung cancer. Zhongguo Fei Ai Za Zhi. 11:377–381. 2008.(In Chinese).
PubMed/NCBI
|
|
20
|
Meyer B, Loeschke S, Schultze A, Weigel T,
Sandkamp M, Goldmann T, Vollmer E and Bullerdiek J: HMGA2
overexpression in non-small cell lung cancer. Mol Carcinog.
46:503–511. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Volm M, Drings P and Wodrich W: Prognostic
significance of the expression of c-fos, c-jun and c-erbB-1
oncogene products in human squamous cell lung carcinomas. J Cancer
Res Clin Oncol. 119:507–510. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gartel AL and Kandel ES: miRNAs: Little
known mediators of oncogenesis. Semin Cancer Biol. 18:103–110.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Farazi TA, Spitzer JI, Morozov P and
Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Garzon R and Marcucci G: Potential of
microRNAs for cancer diagnostics, prognostication and therapy. Curr
Opin Oncol. 24:655–659. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Holland AJ and Cleveland DW: Boveri
revisited: Chromosomal instability, aneuploidy and tumorigenesis.
Nat Rev Mol Cell Biol. 10:478–487. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang Z, Zhuan B, Yan Y, Jiang S and Wang
T: Integrated analyses of copy number variations and gene
differential expression in lung squamous-cell carcinoma. Biol Res.
48:472015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu J and Wei JJ: HMGA2 and high-grade
serous ovarian carcinoma. J Mol Med (Berl). 91:1155–1165. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Di Cello F, Hillion J, Hristov A, Wood LJ,
Mukherjee M, Schuldenfrei A, Kowalski J, Bhattacharya R, Ashfaq R
and Resar LM: HMGA2 participates in transformation in human lung
cancer. Mol Cancer Res. 6:743–750. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wu Y, Song Y and Liu H: Expression and its
clinical significance of HMGA2 in the patients with non-small cell
lung cancer. Zhongguo Fei Ai Za Zhi. 11:377–381. 2008.(In Chinese).
PubMed/NCBI
|
|
30
|
Meyer B, Loeschke S, Schultze A, Weigel T,
Sandkamp M, Goldmann T, Vollmer E and Bullerdiek J: HMGA2
overexpression in non-small cell lung cancer. Mol Carcinog.
46:503–511. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Park SM, Shell S, Radjabi AR, Schickel R,
Feig C, Boyerinas B, Dinulescu DM, Lengyel E and Peter ME: Let-7
prevents early cancer progression by suppressing expression of the
embryonic gene HMGA2. Cell Cycle. 6:2585–2590. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang Y, Zhang P, Zhao Y, Yang J, Jiang G
and Fan J: Decreased MicroRNA-26a expression causes cisplatin
resistance in human non-small cell lung cancer. Cancer Biol Ther.
17:515–525. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xiang Q, Tang H, Yu J, Yin J, Yang X and
Lei X: MicroRNA-98 sensitizes cisplatin-resistant human lung
adenocarcinoma cells by up-regulation of HMGA2. Pharmazie.
68:274–281. 2013.PubMed/NCBI
|
|
34
|
Milde-Langosch K: The fos family of
transcription factors and their role in tumourigenesis. Eur J
Cancer. 41:2449–2461. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chiu R, Boyle WJ, Meek J, Smeal T, Hunter
T and Karin M: The c-Fos protein interacts with c-Jun/AP-1 to
stimulate transcription of AP-1 responsive genes. Cell. 54:541–552.
1988. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Taniguchi S, Kawano T, Mitsudomi T, Kimura
G and Baba T: Fos oncogene transfer to a transformed rat fibroblast
cell line enhances spontaneous lung metastasis in rat. Jpn J Cancer
Res. 77:1193–1197. 1986.PubMed/NCBI
|
